Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Ryszard Pluta
 -- 2488 2022-06-22 20:51:44 |
2 format correction
Dean Liu
 -3 word(s) 2485 2022-06-23 02:38:30 | |
3 All is OK!
Ryszard Pluta
 Meta information modification 2485 2022-07-01 15:13:29 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Pluta, R.;  Januszewski, S.;  Czuczwar, S.J. Molecular Hydrogen Neuroprotection in Post-Ischemic Brain Injury. Encyclopedia. Available online: https://encyclopedia.pub/entry/24363 (accessed on 25 April 2024).
Pluta R,  Januszewski S,  Czuczwar SJ. Molecular Hydrogen Neuroprotection in Post-Ischemic Brain Injury. Encyclopedia. Available at: https://encyclopedia.pub/entry/24363. Accessed April 25, 2024.
Pluta, Ryszard, Sławomir Januszewski, Stanisław J. Czuczwar. "Molecular Hydrogen Neuroprotection in Post-Ischemic Brain Injury" Encyclopedia, https://encyclopedia.pub/entry/24363 (accessed April 25, 2024).
Pluta, R.,  Januszewski, S., & Czuczwar, S.J. (2022, June 22). Molecular Hydrogen Neuroprotection in Post-Ischemic Brain Injury. In Encyclopedia. https://encyclopedia.pub/entry/24363
Pluta, Ryszard, et al. "Molecular Hydrogen Neuroprotection in Post-Ischemic Brain Injury." Encyclopedia. Web. 22 June, 2022.
Molecular Hydrogen Neuroprotection in Post-Ischemic Brain Injury
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms23126591

Molecular hydrogen has gained the attention of both preclinical and clinical researchers. The death of pyramidal neurons in especially the CA1 area of the hippocampus, increased permeability of the blood-brain barrier, neuroinflammation, amyloid accumulation, tau protein dysfunction, brain atrophy, cognitive deficits and dementia are considered an integral part of the phenomena occurring during brain neurodegeneration after ischemia.

brain ischemia neurodegeneration amyloid tau protein

1. Introduction

Molecular hydrogen is an odorless, colorless gas that is physiologically inert. Hydrogen is the lightest and most abundant element in the Earth’s atmosphere. Furthermore, hydrogen is a biological gas that is produced in mammals by intestinal bacteria [1][2][3]. It is believed to be a new type of natural antioxidant with a low ability to react with most biomolecules, which is potentially therapeutic. The first use of hydrogen in humans was hydreliox, a breathing gas mixture of hydrogen, helium and oxygen that is used to prevent decompression sickness and nitrogen narcosis during very deep technical dives [4]. The therapeutic use of hydrogen was first demonstrated in 1975, showing that hyperbaric hydrogen caused marked regression of skin squamous carcinoma in mice [5]. In 2001, hydrogen was documented to have anti-inflammatory properties in experimental parasitic hepatitis [6]. Six years later, it was found that hydrogen was supposed to act as an antioxidant by selectively removing the neurotoxic hydroxyl radical and peroxynitrite from the parenchyma of the rat brain as a result of oxidative stress caused by ischemic brain injury [7]. Hydrogen has been shown to have many advantages as a neuroprotective gas. First, it can penetrate biomembranes, diffuse into the cytosol and organelles and cross the blood-brain barrier [7][8][9]. Secondly, the repeated administration of hydrogen does not cause tolerance [10]. Thirdly, different easy and convenient approaches to administer it are available [11][12]. Fourthly, hydrogen has a protective effect against many diseases, including peripheral and central nervous system diseases such as neuropathic pain, Alzheimer’s disease, stroke, animal cerebral ischemia and neonatal hypoxic-ischemic brain injury [11][13][14][15][16][17][18][19][20][21][22][23]. Fifth, there are no documented serious side effects [13][24]. Sixth, in Japan, 2% molecular hydrogen inhalation has been approved for the clinical treatment of cerebral ischemia due to cardiac arrest [24][25][26][27][28]. The Chinese National Health and Medical Commission in 2020 recommended the use of inhaled hydrogen in addition to oxygen therapy for anti-cancer, anti-inflammatory and anti-oxidant treatments [29]. Hydrogen has been suggested as a new complementary therapy against stroke, which, e.g., reduces oxidative stress, neuroinflammation and apoptosis [22][30][31][32]. Despite many inaccuracies, the selective ability to scavenge free radicals and heal inflammation are still widely accepted mechanisms of the action of hydrogen [32]. Clinical trials have shown that hydrogen treatment is safe and effective in patients with asthma and chronic obstructive pulmonary disease [33][34].
It has been proposed to prevent and treat coronavirus disease by inhaling oxygen mixed with hydrogen (33.4% oxygen and 66.6% hydrogen) due to the important role of hydrogen in alleviating the worsening of lung function, emphysema, and acute or chronic inflammation [29][35][36]. Thus, molecular hydrogen is an interesting potential therapeutic gas for the prevention and treatment of various diseases, including neurological disorders.

2. In Animals

In mice with focal cerebral ischemia with reperfusion, molecular hydrogen significantly increases SOD and GSH-Px activity, reduces malondialdehyde levels and infarct volume, relieves cerebral edema, improves neurological outcomes and alleviates cognitive deficits (Table 1) [19][37][38]. In global cerebral ischemia caused by cardiac arrest in rats, hydrogen inhalation improves neurological outcomes, cognitive deficits and survival [20][39]. Hydrogen injection or inhalation after global cerebral ischemia due to cardiac arrest effectively controls neuronal death and microglia activation in the hippocampus and lowers serum levels of S100b protein (Table 1) [8][31][40]. Inhalation of hydrogen or in combination with hypothermia has been shown to be superior to hypothermia alone in global cerebral ischemia from cardiac arrest in rats [31][40][41]. Molecular hydrogen has been shown to protect the permeability of the blood-brain barrier after focal and global cerebral ischemia (Table 1) [8][9]. Hydrogen has been shown to protect against oxidative stress, neuroinflammation, and prevents the ischemic site from turning into a hemorrhagic focus in rats with local cerebral ischemia (Table 1) [42]. Additionally, it has been shown that the intraperitoneal injection of hydrogen-rich saline has healing properties after transient global cerebral ischemia in rats [43]. Since most of the damage in the above model occurs between 6 and 24 h after ischemia, the effective hydrogen protection period was much less than the 6 h of recirculation, so the protective effect of hydrogen-rich saline in this situation is quite limited [43]. Hydrogen treatment of mice after bilateral closure of the common carotid artery improves cognitive abilities and induces anti-apoptotic and antioxidant effects [44]. In rats, up to 7 days after middle cerebral artery occlusion with reperfusion and administration of hydrogen, a reduction in infarct volume, ischemic penumbra hyperperfusion, neurological and behavioral disorders and white matter damage were observed (Table 1) [45]. It was documented that hydrogen therapy significantly improved the 7-day survival rate of mice after global brain ischemia, from 8.3 to 50% [46]. Histopathological analysis revealed that hydrogen therapy significantly attenuated neuronal injury and autophagy in the hippocampal CA1 area and also brain edema, after 24 h of reperfusion [46]. The beneficial effects of hydrogen therapy on post-ischemic brain injury were associated with significantly lower levels of oxidative stress markers: malondialdehyde and 8-hydroxy-2′-deoxyguanosine in the brain parenchyma [46]. Hydrogen inhalation following 10-min transient global cerebral ischemia in rats that survived 3 days attenuated cognitive impairment [47]. This neuroprotective effect was associated with decreased pyramidal neuronal death in the CA1 region of the hippocampus and inhibition of oxidative stress [47]. Hydrogen inhalation improved survival and neurological deficit after global ischemia caused by cardiac arrest in rats [31]. It also prevented the increase in left ventricular end-diastolic pressure and the increase in serum IL-6 levels, and reduced mortality [31][48][49]. Hydrogen treatment increased the level of interleukin-10, vascular endothelial growth factor and leptin [50]. In addition, a reduction in mortality in rats after cardiac arrest and an effect on the restoration of the bioelectrical activity of the brain was noted [50]. The survival rate at 4 h was 78% in the hydrogen group and 22% in the placebo group [50]. In another global model of cerebral ischemia due to cardiac arrest in rats, increased survival and inhibition of autophagy were observed [51]. Hydrogen inhalation for 4 days improves neurological outcomes and survival after global cerebral ischemia due to cardiac arrest in systemic hypertension rats and is superior to treatment with mild hypothermia [40]. The intraperitoneal injection of hydrogen into rabbits in cardiac arrest improved 3-day survival and neurological deficits, reduced neuronal damage, and inhibited neuronal apoptosis [52]. The intraperitoneal injection of hydrogen decreased the indicators of oxidative stress in the blood and the parenchyma of the hippocampus and increased the activity of the antioxidant enzyme [52]. Rats given hydrogen-rich water before and after occlusion of the middle cerebral artery, surviving up to 14 days after focal ischemia, showed reduced infarct volume and improved neurological outcomes [53]. In addition, hydrogen prevented ischemia-induced decreases in parvalbumin and hypocalcin, and also reduced neuronal cell death induced by toxic glutamate [53]. In addition, hydrogen lowered the increased levels of intracellular Ca2+ caused by glutamate toxicity [53].
Table 1. Neuroprotective effects of molecular hydrogen in experimental post-ischemic brain injury.
Ischemia Animal Strain Treatment Benefits References
Focal Mice C57B/L Inhalation of 66.7% hydrogen/33.3% oxygen for 90 min post-ischemia. Inhibition of microglial activity and regulation of microglial phenotype. Improvement of neurological outcome. [19][37]
Global Mice C57BL/6J Inhalation hydrogen (1.3%), oxygen (30%), and nitrogen (68.7%).
45 min of ischemia and 180 min of reperfusion, and 3 h/d, from 1 to 3 days post-ischemia.		 Improved survival. Attenuation of neuronal injury, autophagy and brain edema. [46]
Global Rat Wistar 2.1% hydrogen supplemented by room air ventilation for 4 h after ischemia. Reduction changes of prooxidant enzyme and gap junction protein levels. [54]
Global Rat Sprague-Dawley Hydrogen-rich saline (5 mL/kg) was injected immediately post-ischemia. Significant improvement of surviving cells. Reduction tissue damage, the degree of mitochondrial swelling, and the loss of mitochondrial membrane potential but also preservation the mitochondrial cytochrome c content. [55]
Global Rat Sprague-Dawley I.V. hydrogen-rich saline (1 mL/kg, 4 mL/kg, or 6 mL/kg),
HRS was given before hypoxia and during reoxygenation.		 Inhibition of hippocampus endoplasmic reticulum stress and microvascular endothelial cells apoptosis via PI3K/Akt/GSK3β signaling pathway. [56]
Global Rat Sprague-Dawley Hydrogen-rich saline 5 mL/kg was intraperitoneally injected immediately and 6 h post-ischemia. Significant improvement survival rate and neurological function. The beneficial effects associated with decreased levels of oxidative products, as well as the increased levels of antioxidant enzymes and accompanied by the increased activity of glucose-regulated protein 78, the decreased activity of cysteinyl aspartate specific proteinase-12 (caspase-12). [57]
Global Rat Wistar Inhalation of 2% hydrogen started immediately at the end of ischemia and lasted for 3 h. Attenuation of cognitive impairment. Decreased pyramidal neuronal death in CA1 region of hippocampus. [47]
Global Rat Sprague-Dawley Hydrogen-rich saline was administered i.v. at 1 min before end of ischemia, followed by injections at 6 and 12 h post-ischemia. Improves survival and neurological outcome. [8]
Focal Rat Sprague-Dawley 6 mL/kg i.p. per rat before and after ischemia. Reduction brain infarct volume and improvement of neurological function. Prevention the ischemia-induced reduction of parvalbumin and hippocalcin levels and also reduced the glutamate toxicity-induced death of neurons. Attenuation the glutamate toxicity-induced by elevate in intracellular calcium. [53]
Focal Rat Sprague-Dawley 0.5 mL/kg/day saturated hydrogen saline (0.6 mmol/L) i.p. 3 days prior to ischemia and immediately during 24 h of reperfusion. Significantly reduction the number of apoptotic cells, and the protein expression of p38 MAPK and caspase-3. These effects may be associated with the p38MAPK signaling pathway. [58]
Focal Rat Sprague-Dawley Hydrogen saline was injected i.p. (1 mL/100 g body weight) at designed time points 0, 3 or 6 h after reperfusion onset. Reduction 8-hydroxyl-2′-deoxyguanosine, malondidehyde, interleukin-1β, tumor necrosis factor-α, and suppressed caspase 3 activity in ischemic brain. [59]
Global Rabbit White Before ischemia i.p. injection of hydrogen low dose (10 mL/kg) or high dose (20 mL/kg). Improvement survival and neurological outcomes, reduction of neuronal damage and inhibition of neuronal apoptosis. Reduction indicators of oxidative stress in the blood and the hippocampus and increased activity of antioxidant enzyme. [52]
Global Swine Yorkshire Inhalation of hydrogen (2.40%) for a 24-h period during and after the ischemic injury. Reduced neurological injury. [60]
Subsequent studies found that rats that underwent global cerebral ischemia and were treated with hydrogen-rich saline had milder neuronal injury and a limited number of irreversibly damaged neurons in the brain [15]. Expression of miR-210, miR21 and NF-κB in the ischemic hippocampus at 6, 24 and 96 h was significantly reduced in the hydrogen-treated group [15]. Moreover, the number of Tregs cells after cerebral ischemia treated with hydrogen increased on days one and four after reperfusion [15]. These results indicate that the recovery from global cerebral ischemia in rats dosed with hydrogen-rich saline is most likely associated with an upregulation of Treg cell numbers [15]. Hydrogen significantly increased the number of surviving ischemic pyramidal neurons in the CA1 region of the hippocampus [15]. In addition, the neurobehavioral test confirmed that hydrogen reduced damage to the brain after ischemia [15]. This neuroprotective effect may be due to the extensive spread of hydrogen throughout the brain. Hydrogen has a good diffusion rate, can easily penetrate the blood-brain barrier and reach deep brain structures, and is also able to reach the site of injury before revascularization to remove toxic oxygen free radicals [61].
In behavioral studies of rats after focal cerebral ischemia, administration of lactulose, which induces endogenous hydrogen production in the intestine, resulted in higher neurological scores and shorter escape latency in the Morris test [62]. Morphological studies using 2,3,5-triphenyltetrazolium chloride showed a smaller infarct volume, Nissel staining showed relatively distinct and intact neuronal cells and TUNEL staining showed fewer apoptotic neurons [62]. In biochemical studies, lactulose decreased the content of malondialdehyde in the brain, the activity of caspase-3, the concentration of 3-nitrotyrosine and 8-hydroxy-2-deoxyguanosine and increased the activity of superoxide dismutase [62]. Orally administered lactulose activated expression of NF-E2 related factor 2 (Nrf2) in the brain [62]. The antibiotics suppressed the neuroprotective effects of lactulose by reducing hydrogen generation [62]. Lactulose administered intragastrically had a neuroprotective effect in post-ischemic brain injury in rats, which is attributed to the production of hydrogen via fermentation of lactulose by intestinal bacteria and activation of Nrf2 [62].
Studies that assessed the most effective timing of hydrogen administration after local cerebral ischemia in rats showed a post-ischemic time interval of up to 6 h during which significant reductions in infarct volume and brain edema were observed, and neurological outcomes improved [59]. At that time, after local cerebral ischemia, hydrogen decreased 8-hydroxyl-2′-deoxyguanosine (8-OHdG), reduced the content of malondialdehyde, interleukin-1β, tumor necrosis factor-α and suppressed caspase 3 activity [59]. These results indicate that hydrogen has a neuroprotective effect when administered during 6 h post-ischemia [59].
One study used hydrogen-saturated saline for focal cerebral ischemia in rats to test whether hydrogen-saturated saline reduces apoptosis of neuronal cells through the p38 MAPK-caspase-3 signaling pathway [58]. The obtained data showed that hydrogen reduced apoptotic neuronal cell death and infiltration of inflammatory cells in the brain cortex of rats post-ischemia [58]. In the hydrogen-treated group, there was a significant decrease in p38 MAPK protein expression compared to the untreated group [58]. It was concluded that hydrogen-rich saline could exert anti-apoptotic neuroprotective effects via the p38 MAPK signaling pathway [58]. It has also been found that, in acute post-ischemic brain injury in mice, hydrogen reduces the levels of Bax and TNFα and induces an anti-inflammatory response by regulating IL-2 and IL-10 [44].

3. In Humans

Studies in patients with acute focal cerebral ischemia have shown that administration of molecular hydrogen by inhalation or intravenous infusion is safe, hydrogen has been found in the blood, and there was no effect of hydrogen on physiological parameters [13][25][63]. Patients with local cerebral infarction who received hydrogen inhalation as part of their treatment had a reduced infarct size, improved neurological outcomes and the ability to perform daily activities compared to untreated patients (Table 2) [16]. In a human study of global cerebral ischemia due to cardiac arrest, inhalation of low concentration molecular hydrogen positively affected brain function without adverse events (Table 2) [25]. In Japan, a phase II clinical trial was conducted in patients with cerebral ischemia after cardiac arrest, finding a positive effect on neurological functioning and the safety of molecular hydrogen inhalation (Table 2) [25][27]. While no side effects of hydrogen have been detected in animal studies, potential side effects should still be investigated due to diarrhea reported by a small number of patients after receiving hydrogen [63].
Table 2. Neuroprotective effects of molecular hydrogen in clinical post-ischemic brain injury.
Ischemia Number of Participants Treatment Benefits Study References
Focal 50 patients Inhalation 3% hydrogen gas (1 h twice a day) for initial 7 days. Reduced infarct size, improved neurological outcome and daily living activity. Randomized [16]
Global 5 patients 2% hydrogen with oxygen was supplied via a respirator
after admission to the intensive care unit for 18 h.		 4 patients survived 90 days with a favorable neurological outcome. Pilot study [25]
Global 360 patients 2% hydrogen with 24 to 50% oxygen was supplied via mechanical ventilation
after admission for 18 h.		 The first multicenter randomized trial is underway to confirm the efficacy of hydrogen on neurological outcomes in comatose out-of-hospital cardiac arrest survivors. Randomized, double-blind, placebo-controlled trial. [26]
Global 5 patients Inhalation 2% hydrogen with titrated oxygen was initiated upon admission for 18 h. Oxidative stress markers were reduced in cardiogenic post-cardiac arrest patients but were slightly elevated in the patient with sepsis. Inflammatory cytokine levels remained unchanged in cardiogenic post-cardiac arrest patients, whereas a dramatic reduction was observed in one patient with sepsis. Pilot study [27]

References

  1. Ohta, S. Molecular hydrogen is a novel antioxidant to efficiently reduce oxidative stress with potential for the improvement of mitochondrial diseases. Biochim. Biophys. Acta 2012, 1820, 586–594.
  2. Zhou, J.; Wu, P.-F.; Wang, F.; Chen, J.-G. Targeting gaseous molecules to protect against cerebral ischaemic injury: Mechanisms and prospects. Clin. Exp. Pharmacol. Physiol. 2012, 39, 566–576.
  3. Htun, Y.; Nakamura, S.; Kusaka, T. Hydrogen and therapeutic gases for neonatal hypoxic-ischemic encephalopathy: Potential neuroprotective adjuncts in translational research. Pediatr. Res. 2021, 89, 753–759.
  4. Lanphier, E.H. Human respiration under increased pressures. Symp. Soc. Exp. Biol. 1972, 26, 379–394.
  5. Dole, M.; Wilson, F.R.; Fife, W.P. Hyperbaric hydrogen therapy: A possible treatment for cancer. Science 1975, 190, 152–154.
  6. Gharib, B.; Hanna, S.; Abdallahi, O.M.; Lepidi, H.; Gardette, B.; De Reggi, M. Anti-inflammatory properties of molecular hydrogen: Investigation on parasite-induced liver inflammation. Comptes Rendus L’académie Sci.-Ser. III-Sci. Vie 2001, 324, 719–724.
  7. Ohsawa, I.; Ishikawa, M.; Takahashi, K.; Watanabe, M.; Nishimaki, K.; Yamagata, K.; Katsura, K.; Katayama, Y.; Asoh, S.; Ohta, S. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat. Med. 2007, 13, 688–694.
  8. Huo, T.-T.; Zeng, Y.; Liu, X.-N.; Sun, L.; Han, H.-Z.; Chen, H.-G.; Lu, Z.-H.; Huang, Y.; Nie, H.; Dong, H.-L.; et al. Hydrogen rich saline improves survival and neurological outcome after cardiac arrest and cardiopulmonary resuscitation in rats. Anesth. Analg. 2014, 119, 368–380.
  9. Takeuchi, S.; Nagatani, K.; Otani, N.; Nawashiro, H.; Sugawara, T.; Wada, K.; Mori, K. Hydrogen improves neurological function through attenuation of blood-brain barrier disruption in spontaneously hypertensive stroke-prone rats. BMC Neurosci. 2015, 16, 22.
  10. Ge, Y.; Wu, F.; Sun, X.; Xiang, Z.; Yang, L.; Huang, S.; Lu, Z.; Sun, Y.; Yu, W.-F. Intrathecal infusion of hydrogen-rich normal saline attenuates neuropathic pain via inhibition of activation of spinal astrocytes and microglia in rats. PLoS ONE 2014, 9, e97436.
  11. Iketani, M.; Ohsawa, I. Molecular hydrogen as a neuroprotective agent. Curr. Neuropharmacol. 2017, 15, 324–331.
  12. Liu, B.; Qin, S. Different types of molecular hydrogen donors and their pharmacokinetics in vivo. Sheng Li Xue Bao 2019, 71, 371–377.
  13. Ono, H.; Nishijima, Y.; Adachi, N.; Sakamoto, M.; Kudo, Y.; Nakazawa, J.; Nakao, A. Hydrogen (H2) treatment for acute erythymatous skin diseases. A report of 4 patients with safety data and a non-controlled feasibility study with H2 concentration measurement on two volunteers. Med. Gas Res. 2012, 2, 14.
  14. Kawaguchi, M.; Satoh, Y.; Otsubo, Y.; Kazama, T. Molecular hydrogen attenuates neuropathic pain in mice. PLoS ONE 2014, 9, e100352.
  15. Li, Q.; Yu, P.; Zeng, Q.; Luo, B.; Cai, S.; Hui, K.; Yu, G.; Zhu, C.; Chen, X.; Duan, M.; et al. Neuroprotective effect of hydrogen-rich saline in global cerebral ischemia/reperfusion rats: Up-regulated tregs and down-regulated miR-21, miR-210 and NF-jB expression. Neurochem. Res. 2016, 41, 2655–2665.
  16. Ono, H.; Nishijima, Y.; Ohta, S.; Sakamoto, M.; Kinone, K.; Horikosi, T.; Tamaki, M.; Takeshita, H.; Futatuki, T.; Ohishi, W.; et al. Hydrogen gas inhalation treatment in acute cerebral infarction: A randomized controlled clinical study on safety and neuroprotection. J. Stroke Cerebrovasc. Dis. 2017, 26, 2587–2594.
  17. Hou, C.; Peng, Y.; Qin, C.; Fan, F.; Liu, J.; Long, J. Hydrogen-rich water improves cognitive impairment gender-dependently in APP/PS1 mice without affecting Ab clearance. Free. Radic. Res. 2018, 52, 1311–1322.
  18. Wang, H.; Huo, X.; Chen, H.; Li, B.; Liu, J.; Ma, W.; Wang, X.; Xie, K.; Yu, Y.; Shi, K. Hydrogen rich saline activated autophagy via HIF-1a pathways in neuropathic pain model. BioMed Res. Int. 2018, 2018, 4670834.
  19. Huang, J.; Liu, W.; Manaenko, A.; Sun, X.; Mei, Q.; Hu, Q. Hydrogen inhibits microglial activation and regulates microglial phenotype in a mouse middle cerebral artery occlusion model. Med. Gas Res. 2019, 9, 127–132.
  20. Huang, L.; Applegate, R.L., II; Applegate, P.M.; Gong, L.; Ocak, U.; Boling, W.; Zhang, J.H. Inhalation of high-concentration hydrogen gas attenuates cognitive deficits in a rat model of asphyxia induced cardiac arrest. Med. Gas Res. 2019, 9, 122–126.
  21. Wang, Y.-Z.; Li, T.-T.; Cao, H.-L.; Yang, W.-C. Recent advances in the neuroprotective effects of medical gases. Med. Gas Res. 2019, 9, 80–87.
  22. Zhang, Z.-Y.; Fang, Y.-J.; Luo, Y.-J.; Lenahan, C.; Zhang, J.-M.; Chen, S. The role of medical gas in stroke: An updated review. Med. Gas Res. 2019, 9, 221–228.
  23. Zhang, L.; Zhao, P.; Yue, C.; Jin, Z.; Liu, Q.; Du, X.; He, Q. Sustained release of bioactive hydrogen by Pd hydride nanoparticles overcomes Alzheimer’s disease. Biomaterials 2019, 197, 393–404.
  24. Ono, H.; Nishijima, Y.; Adachi, N.; Sakamoto, M.; Kudo, Y.; Kaneko, K.; Nakao, A.; Imaoka, T. A basic study on molecular hydrogen (H2) inhalation in acute cerebral ischemia patients for safety check with physiological parameters and measurement of blood H2 level. Med. Gas Res. 2012, 2, 21.
  25. Tamura, T.; Hayashida, K.; Sano, M.; Suzuki, M.; Shibusawa, T.; Yoshizawa, J.; Kobayashi, Y.; Suzuki, T.; Ohta, S.; Morisaki, H.; et al. Feasibility and safety of hydrogen gas inhalation for post-cardiac arrest syndrome—First in human pilot study. Circ. J. 2016, 80, 1870–1873.
  26. Tamura, T.; Hayashida, K.; Sano, M.; Onuki, S.; Suzuki, M. Efficacy of inhaled hydrogen on neurological outcome following brain ischemia during post-cardiac arrest care (HYBRID II trial): Study protocol for a randomized controlled trial. Trials 2017, 18, 488.
  27. Tamura, T.; Suzuki, M.; Hayashida, K.; Kobayashi, Y.; Yoshizawa, J.; Shibusawa, T. Hydrogen gas inhalation alleviates oxidative stress in patients with post-cardiac arrest syndrome. J. Clin. Biochem. Nutr. 2020, 67, 214–221.
  28. Chen, W.; Zhang, H.-T.; Qin, S.-C. Neuroprotective effects of molecular hydrogen: A critical review. Neurosci. Bull. 2021, 37, 389–404.
  29. Sano, M.; Tamura, T. Hydrogen gas therapy: From preclinical studies to clinical trials. Curr. Pharm. Des. 2021, 27, 650–665.
  30. Li, H.; Luo, Y.; Yang, P.; Liu, J. Hydrogen as a complementary therapy against ischemic stroke: A review of the evidence. J. Neurol. Sci. 2019, 396, 240–246.
  31. Hayashida, K.; Sano, M.; Kamimura, N.; Yokota, T.; Suzuki, M.; Ohta, S.; Fukuda, K.; Hori, S. Hydrogen inhalation during normoxic resuscitation improves neurological outcome in a rat model of cardiac arrest independently of targeted temperature management. Circulation 2014, 130, 2173–2180.
  32. Tian, Y.; Zhang, Y.; Wang, Y.; Chen, Y.; Fan, W.; Zhou, J.; Qiao, J.; Wei, Y. Hydrogen, a novel therapeutic molecule, regulates oxidative stress, inflammation, and apoptosis. Front. Physiol. 2021, 12, 789507.
  33. Wang, S.-T.; Bao, C.; He, Y.; Tian, X.; Yang, Y.; Zhang, T. Hydrogen gas (XEN) inhalation ameliorates airway inflammation in asthma and COPD patients. QJM Int. J. Med. 2020, 113, 870–875.
  34. Zheng, Z.-G.; Sun, W.-Z.; Hu, J.-Y.; Jie, Z.-J.; Xu, J.-F.; Cao, J.; Song, Y.-L.; Wang, C.-H.; Wang, J.; Zhao, H.; et al. Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: Results of a multicenter, randomized, double-blind, parallel-group controlled trial. Respir. Res. 2021, 22, 149.
  35. Guan, W.-J.; Chen, R.-C.; Zhong, N.-S. Strategies for the prevention and management of coronavirus disease 2019. Eur. Respir. J. 2020, 55, 2000597.
  36. Guan, W.-J.; Wei, C.-H.; Chen, A.-L.; Sun, X.-C.; Guo, G.-Y.; Zou, X.; Shi, J.-D.; Lai, P.-Z.; Zheng, Z.-G.; Zhong, N.-S. Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with coronavirus disease 2019 in a recent multicenter, open-label clinical trial. J. Thorac. Dis. 2020, 12, 3448–3452.
  37. Huang, J.; Liu, W.; Sun, X. Hydrogen inhalation improves mouse neurological outcomes after cerebral ischemia/reperfusion independent of anti-necroptosis. Med. Gas Res. 2018, 8, 1–5.
  38. Chen, L.; Chao, Y.; Cheng, P.; Li, N.; Zheng, H.; Yang, Y. UPLCQTOF/MS-based metabolomics reveals the protective mechanism of hydrogen on mice with ischemic stroke. Neurochem. Res. 2019, 44, 1950–1963.
  39. Huang, L.; Applegate, R.L., II; Applegate, P.M.; Boling, W.; Zhang, J.H. Inhalation of high concentration hydrogen gas improves shortterm outcomes in a rat model of asphyxia induced-cardiac arrest. Med. Gas Res. 2018, 8, 73–78.
  40. Chen, G.; Chen, B.; Dai, C.; Wang, J.; Wang, J.; Huang, Y.; Li, Y. Hydrogen inhalation is superior to mild hypothermia for improving neurological outcome and survival in a cardiac arrest model of spontaneously hypertensive rat. Shock 2018, 50, 689–695.
  41. Wang, P.; Jia, L.; Chen, B.; Zhang, L.; Liu, J.; Long, J.; Li, Y. Hydrogen inhalation is superior to mild hypothermia in improving cardiac function and neurological outcome in an asphyxial cardiac arrest model of rats. Shock 2016, 46, 312–318.
  42. Chen, C.H.; Manaenko, A.; Zhan, Y.; Liu, W.W.; Ostrowki, R.P.; Tang, J.; Zhang, J.H. Hydrogen gas reduced acute hyperglycemia-enhanced hemorrhagic transformation in a focal ischaemia rat model. Neuroscience 2010, 169, 402–414.
  43. Ji, Q.; Hui, K.; Zhang, L.; Sun, X.; Li, W.; Duan, M. The effect of hydrogen-rich saline on the brain of rats with transient ischemia. J. Surg. Res. 2011, 168, e95–e01.
  44. Lee, D.; Choi, J.-I. Hydrogen-rich water improves cognitive ability and induces antioxidative, antiapoptotic, and anti-inflammatory effects in an acute ischemia-reperfusion injury mouse model. BioMed Res. Int. 2021, 9956938, 12p.
  45. Jiang, Z.; Alamuri, T.T.; Muir, E.R.; Choi, D.W.; Duong, T.Q. Longitudinal multiparametric MRI study of hydrogen-enriched water with minocycline combination therapy in experimental ischemic stroke in rats. Brain Res. 2020, 1748, 147122.
  46. Nagatani, K.; Wada, K.; Takeuchi, S.; Kobayashi, H.; Uozumi, Y.; Otani, N.; Fujita, M.; Tachibana, S.; Nawashiro, H. Effect of hydrogen gas on the survival rate of mice following global cerebral ischemia. Shock 2012, 37, 645–652.
  47. Ge, P.; Zhao, J.; Li, S.; Ding, Y.; Yang, F.; Luo, Y. Inhalation of hydrogen gas attenuates cognitive impairment in transient cerebral ischemia via inhibition of oxidative stress. Neurol. Res. 2012, 34, 187–194.
  48. Hayashida, K.; Sano, M.; Kamimura, N.; Yokota, T.; Suzuki, M.; Maekawa, Y.; Kawamura, A.; Abe, T.; Ohta, S.; Fukuda, K.; et al. H2 gas improves functional outcome after cardiac arrest to an extent comparable to therapeutic hypothermia in a rat model. J. Am. Heart Assoc. 2012, 1, e003459.
  49. Hayashida, K.; Miyara, S.J.; Shinozaki, K.; Takegawa, R.; Yin, T.; Rolston, D.M.; Choudhary, R.C.; Guevara, S.; Molmenti, E.P.; Becker, L.B. Inhaled gases as therapies for post-cardiac arrest syndrome: A narrative review of recent developments. Front. Med. 2021, 7, 586229.
  50. Yin, T.; Becker, L.B.; Choudhary, R.C.; Takegawa, R.; Shoaib, M.; Shinozaki, K.; Endo, Y.; Homma, K.; Rolston, D.M.; Eguchi, S.; et al. Hydrogen gas with extracorporeal cardiopulmonary resuscitation improves survival after prolonged cardiac arrest in rats. J. Transl. Med. 2021, 19, 462.
  51. Gong, X.; Fan, X.; Yin, X.; Xu, T.; Li, J.; Guo, J.; Zhao, X.; Wei, S.; Yuan, Q.; Wang, J.; et al. Hydrogen therapy after resuscitation improves myocardial injury involving inhibition of autophagy in an asphyxial rat model of cardiac arrest. Exp. Ther. Med. 2022, 23, 376.
  52. Huang, G.; Zhou, J.; Zhan, W.; Xiong, Y.; Hu, C.; Li, X.; Li, X.; Li, Y.; Liao, X. The neuroprotective effects of intraperitoneal injection of hydrogen in rabbits with cardiac arrest. Resuscitation 2013, 84, 690–695.
  53. Han, L.; Tian, R.; Yan, H.; Pei, L.; Hou, Z.; Hao, S.; Li, Y.V.; Tian, Q.; Liu, B.; Zhang, Q. Hydrogen-rich water protects against ischemic brain injury in rats by regulating calcium buffering proteins. Brain Res. 2015, 1615, 129–138.
  54. Hugyecz, M.; Mracskó, E.; Hertelendy, P.; Farkas, E.; Domoki, F.; Bari, F. Hydrogen supplemented air inhalation reduces changes of prooxidant enzyme and gap junction protein levels after transient global cerebral ischemia in the rat hippocampus. Brain Res. 2011, 1404, 31–38.
  55. Cui, Y.; Zhang, H.; Ji, M.; Jia, M.; Chen, H.; Yang, J.; Duan, M. Hydrogen-rich saline attenuates neuronal ischemia-reperfusion injury by protecting mitochondrial function in rats. J. Surg. Res. 2014, 192, 564–572.
  56. Chen, K.; Wang, N.; Diao, Y.; Dong, W.; Sun, Y.; Liu, L.; Wu, X. Hydrogen-rich saline attenuates brain injury induced by cardiopulmonary bypass and inhibits microvascular endothelial cell apoptosis via the PI3K/Akt/GSK3b signaling pathway in rats. Cell. Physiol. Biochem. 2017, 43, 1634–1647.
  57. Gao, Y.; Gui, Q.; Jin, L.; Yu, P.; Wu, L.; Cao, L.; Wang, Q.; Duan, M. Hydrogen-rich saline attenuates hippocampus endoplasmic reticulum stress after cardiac arrest in rats. Neurosci. Lett. 2017, 640, 29–36.
  58. Li, D.; Ai, Y. Hydrogen saline suppresses neuronal cell apoptosis and inhibits the p38 mitogen-activated protein kinase-caspase-3 signaling pathway following cerebral ischemia-reperfusion injury. Mol. Med. Rep. 2017, 16, 5321–5325.
  59. Liu, Y.; Liu, W.; Sun, X.; Li, R.; Sun, Q.; Cai, J.; Kang, Z.; Lv, S.; Zhang, J.H.; Zhang, W. Hydrogen saline offers neuroprotection by reducing oxidative stress in a focal cerebral ischemia-reperfusion rat model. Med. Gas Res. 2011, 1, 15.
  60. Cole, A.R.; Perry, D.A.; Raza, A.; Nedder, A.P.; Pollack, E.; Regan, W.L.; van den Bosch, S.J.; Polizzotti, B.D.; Yang, E.; Davila, D.; et al. Perioperatively inhaled hydrogen gas diminishes neurologic injury following experimental circulatory arrest in swine. JACC Basic Transl. Sci. 2019, 4, 176–187.
  61. Jiang, Z.; Li, C.; Manuel, M.L.; Yuan, S.; Kevil, C.G.; McCarter, K.D.; Lu, W.; Sun, H. Role of hydrogen sulfide in early blood-brain barrier disruption following transient focal cerebral ischemia. PLoS ONE 2015, 10, e0117982.
  62. Zhai, X.; Chen, X.; Shi, J.; Shi, D.; Ye, Z.; Liu, W.; Li, M.; Wang, Q.; Kang, Z.; Bi, H.; et al. Lactulose ameliorates cerebral ischemia–reperfusion injury in rats by inducing hydrogen by activating Nrf2 expression. Free Radic. Biol. Med. 2013, 65, 731–741.
  63. Nagatani, K.; Nawashiro, H.; Takeuchi, S.; Tomura, S.; Otani, N.; Osada, H.; Wada, K.; Katoh, H.; Tsuzuki, N.; Mori, K. Safety of intravenous administration of hydrogen-enriched fluid in patients with acute cerebral ischemia: Initial clinical studies. Med. Gas Res. 2013, 3, 13.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Pathology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Ryszard Pluta
,
Sławomir Januszewski
,
Stanisław J. Czuczwar
View Times: 498
Entry Collection: Neurodegeneration
Revisions: 3 times (View History)
Update Date: 01 Jul 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback